Switch theme
Sign up to access all valuation multiples
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
2012
38
LTM Revenue $0.9M
LTM EBITDA n/a
$19.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cidara Therapeutics has a last 12-month revenue of $0.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cidara Therapeutics achieved revenue of $1.3M and an EBITDA of -$176M.
Cidara Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cidara Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $63.9M | $1.3M | XXX | XXX | XXX |
| Gross Profit | n/a | $62.4M | XXX | XXX | XXX |
| Gross Margin | NaN% | 4893% | XXX | XXX | XXX |
| EBITDA | -$24.4M | -$176M | XXX | XXX | XXX |
| EBITDA Margin | -38% | -13794% | XXX | XXX | XXX |
| Net Profit | -$29.8M | -$22.9M | XXX | XXX | XXX |
| Net Margin | -47% | -1799% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cidara Therapeutics's stock price is $19.
Cidara Therapeutics has current market cap of $205M, and EV of $19.0M.
See Cidara Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.0M | $205M | XXX | XXX | XXX | XXX | $-21.99 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cidara Therapeutics has market cap of $205M and EV of $19.0M.
Cidara Therapeutics's trades at 20.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cidara Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cidara Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $19.0M | XXX | XXX | XXX |
| EV/Revenue | 14.9x | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | XXX | XXX |
| P/E | -1.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCidara Therapeutics's NTM/LTM revenue growth is -100%
Cidara Therapeutics's revenue per employee for the last fiscal year averaged $34K, while opex per employee averaged $4.7M for the same period.
Over next 12 months, Cidara Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cidara Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cidara Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -98% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -13794% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 622% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $34K | XXX | XXX | XXX | XXX |
| Opex per Employee | $4.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1617% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12295% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 13912% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cidara Therapeutics acquired XXX companies to date.
Last acquisition by Cidara Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cidara Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cidara Therapeutics founded? | Cidara Therapeutics was founded in 2012. |
| Where is Cidara Therapeutics headquartered? | Cidara Therapeutics is headquartered in United States of America. |
| How many employees does Cidara Therapeutics have? | As of today, Cidara Therapeutics has 38 employees. |
| Who is the CEO of Cidara Therapeutics? | Cidara Therapeutics's CEO is Dr. Jeffrey Stein, PhD. |
| Is Cidara Therapeutics publicy listed? | Yes, Cidara Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Cidara Therapeutics? | Cidara Therapeutics trades under CDTX ticker. |
| When did Cidara Therapeutics go public? | Cidara Therapeutics went public in 2015. |
| Who are competitors of Cidara Therapeutics? | Similar companies to Cidara Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cidara Therapeutics? | Cidara Therapeutics's current market cap is $205M |
| What is the current revenue of Cidara Therapeutics? | Cidara Therapeutics's last 12-month revenue is $0.9M. |
| What is the current EV/Revenue multiple of Cidara Therapeutics? | Current revenue multiple of Cidara Therapeutics is 20.9x. |
| What is the current revenue growth of Cidara Therapeutics? | Cidara Therapeutics revenue growth between 2023 and 2024 was -98%. |
| Is Cidara Therapeutics profitable? | Yes, Cidara Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
